Blood test may predict clot risk in rare blood cancers
NCT ID NCT07119970
First seen Jan 14, 2026 · Last updated May 25, 2026 · Updated 21 times
Summary
This study is for people with myeloproliferative neoplasms (MPNs), a group of blood cancers that raise the risk of dangerous blood clots. Researchers want to see if a marker called calprotectin in the blood can help predict who will get a clot. 300 participants will be followed over time to compare those who develop clots with those who don't.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques
NOT_YET_RECRUITINGParis, 75010, France
Contact Email: •••••@•••••
-
APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire
NOT_YET_RECRUITINGLe Kremlin-Bicêtre, 94270, France
Contact Email: •••••@•••••
-
APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire
NOT_YET_RECRUITINGCréteil, 94010, France
Contact Email: •••••@•••••
-
CH de Libourne, Service Hématologie
RECRUITINGLibourne, 33505, France
Contact Email: •••••@•••••
-
CH de Roubaix, Service Hématologie
NOT_YET_RECRUITINGRoubaix, 59100, France
Contact Email: •••••@•••••
-
CH de la Côte Basque, Service Hématologie
NOT_YET_RECRUITINGBayonne, 64100, France
Contact Email: •••••@•••••
-
CH des Pays de Morlaix, Service Onco-Hématologie
NOT_YET_RECRUITINGMorlaix, 29672, France
Contact Email: •••••@•••••
-
CHD de Vendée, Service Onco-hématologie
NOT_YET_RECRUITINGLa Roche-sur-Yon, 85925, France
Contact Email: •••••@•••••
-
CHU d'Angers, Service des maladies du Sang
NOT_YET_RECRUITINGAngers, 49933, France
Contact Email: •••••@•••••
-
CHU de Bordeaux, Service Hématologie Biologique
NOT_YET_RECRUITINGBordeaux, 33600, France
Contact Email: •••••@•••••
-
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
NOT_YET_RECRUITINGBordeaux, 33600, France
Contact Email: •••••@•••••
-
CHU de Brest, Service Hématologie et Hémostase Clinique
NOT_YET_RECRUITINGBrest, 29609, France
Contact Email: •••••@•••••
-
CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire
NOT_YET_RECRUITINGLimoges, 87042, France
Contact Email: •••••@•••••
-
CHU de Nantes, Service Hématologie Clinique
NOT_YET_RECRUITINGNantes, 44093, France
Contact Email: •••••@•••••
-
Hôpital Privé du Confluent, Service Hématologie
NOT_YET_RECRUITINGNantes, 44202, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.